These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 18787370)

  • 1. Hemorrhagic pericarditis with cardiac tamponade after percutaneous coronary intervention associated with the use of abciximab.
    Moon SJ; Yoon HJ; Her SH; Lee JM; An HJ; Lee YJ; Jin SW
    Korean J Intern Med; 2008 Sep; 23(3):156-60. PubMed ID: 18787370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemorrhagic Pericarditis Leading to Cardiac Tamponade Following Abciximab Therapy.
    Inayat F; Mirza F; Sultan Rai AB
    J Coll Physicians Surg Pak; 2016 May; 26(5):447-8. PubMed ID: 27225159
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
    Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
    Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
    Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
    Kimmelstiel C; Phang R; Rehman A; Rand W; Miele R; Rhofiry J; MacIsaac DA; Gouveia W; Denier D; Becker RC
    J Thromb Thrombolysis; 2001 May; 11(3):203-9. PubMed ID: 11577258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab.
    Cote AV; Berger PB; Holmes DR; Scott CG; Bell MR
    Mayo Clin Proc; 2001 Sep; 76(9):890-6. PubMed ID: 11560299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
    Lincoff AM; Bittl JA; Harrington RA; Feit F; Kleiman NS; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Kereiakes DJ; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
    JAMA; 2003 Feb; 289(7):853-63. PubMed ID: 12588269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Right ventricular perforation with cardiac tamponade associated with use of a temporary pacing wire and abciximab during complex coronary angioplasty.
    Nashed G; French B; Gallagher D; Hopkins A; Juergens C; Leung D; Lowe HC
    Catheter Cardiovasc Interv; 1999 Dec; 48(4):388-9. PubMed ID: 10559821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
    Cho L; Topol EJ; Balog C; Foody JM; Booth JE; Cabot C; Kleiman NS; Tcheng JE; Califf R; Lincoff AM
    J Am Coll Cardiol; 2000 Aug; 36(2):381-6. PubMed ID: 10933346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy.
    Wöhrle J; Merkle N; Kunze M; Cristea E; Mehran R; Rottbauer W; Stone GW
    Catheter Cardiovasc Interv; 2012 Jun; 79(7):1083-9. PubMed ID: 22162175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute profound thrombocytopenia following abciximab therapy.
    Bishara AI; Hagmeyer KO
    Ann Pharmacother; 2000; 34(7-8):924-30. PubMed ID: 10928405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracoronary use of GP IIb/IIIa inhibitors in percutaneous coronary interventions.
    De Vita M; Coluccia V; Burzotta F; Romagnoli E; Trani C
    Curr Vasc Pharmacol; 2012 Jul; 10(4):448-53. PubMed ID: 22339256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.
    Kereiakes DJ; Berkowitz SD; Lincoff AM; Tcheng JE; Wolski K; Achenbach R; Melsheimer R; Anderson K; Califf RM; Topol EJ
    Am Heart J; 2000 Jul; 140(1):74-80. PubMed ID: 10874266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.
    Labinaz M; Ho C; Banerjee S; Martin J; Chen S; Mensinkai S
    Can J Cardiol; 2007 Oct; 23(12):963-70. PubMed ID: 17932572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleeding complications of platelet glycoprotein IIb/IIIa inhibitor abciximab (ReoPro ).
    Trivedi SM; Shani J; Hollander G
    J Invasive Cardiol; 2002 Jul; 14(7):423-5. PubMed ID: 12082199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? No.
    Ragosta M; Sarembock IJ
    J Thromb Haemost; 2004 Jan; 2(1):10-2. PubMed ID: 14717959
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.